
Drugmaker Amgen's AMGN.O shares fall 2.8% to $281 in extended trading
Company says U.S. FDA placed a clinical hold on an early-stage study for its experimental weight-loss drug AMG 513
Amgen says discussions are underway on a path forward to reopen the study
Company posts Q4 adj profit of $5.31/shr vs analysts' average est. of $5.08/shr - LSEG
Up to last close, stock down 10.2% in the last 12 months